Prediction of clopidogrel efficacy and safety: phenotyping and/or genotyping?

References

• Brar SS, ten Berg J, Marcucci R et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J. Am. Coll. Cardiol. 58(19), 1945–1954 (2011).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Braun S et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb. Haemost. 103(1), 151–159 (2010).
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8), 754–762 (2010).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8), 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4), 512–518 (2010).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Delle-Karth G, Lang IM et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J. Thromb. Haemost. 10(4), 529–542 (2012).
   PubMed Web of Science ®Google Scholar
• Stone GW. ADAPT-DES: a large-scale, prospective, multicenter registry examining the relationship of platelet responsiveness to stent thrombosis after DES implantation. Presented at: TCT 2011: Transcatheter Cardiovascular Therapeutics 23rd Annual Scientific Symposium. San Francisco, CA, USA, 7–11 November 2011.
   Google Scholar
• Ahn SG, Lee SH, Yoon JH et al. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. JACC. Cardiovasc. Interv. 5(3), 259–267 (2012).
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R et al.; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56(12), 919–933 (2010).
   PubMed Web of Science ®Google Scholar
• Campo G, Parrinello G, Ferraresi P et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J. Am. Coll. Cardiol. 57(25), 2474–2483 (2011).
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16), 1821–1830 (2010).
   PubMed Web of Science ®Google Scholar
• Giusti B, Gori AM, Marcucci R et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am. J. Cardiol. 103(6), 806–811 (2009).
   PubMed Web of Science ®Google Scholar
• Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 11(3), 199–206 (2011).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Shuldiner AR, Bliden KP, Ryan K, Pakyz RE, Tantry US. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am. Heart J. 161(3), 598–604 (2011).
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660), 309–317 (2009).
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Fromm MF et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J. Am. Coll. Cardiol. 55(22), 2427–2434 (2010).
   PubMed Web of Science ®Google Scholar
• Cayla G, Hulot JS, O’Connor SA et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 306(16), 1765–1774 (2011).
   PubMed Web of Science ®Google Scholar
• Roberts JD, Wells GA, Le May MR et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379(9827), 1705–1711 (2012).
   PubMed Web of Science ®Google Scholar
• Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 57(19), 1920–1959 (2011).
   PubMed Web of Science ®Google Scholar